PMID- 15344695
OWN - NLM
STAT- MEDLINE
DCOM- 20041213
LR  - 20061115
IS  - 0023-2149 (Print)
IS  - 0023-2149 (Linking)
VI  - 82
IP  - 6
DP  - 2004
TI  - [Efficacy of nebulized budesonide in severe exacerbation of bronchial asthma].
PG  - 61-6
AB  - The study was undertaken to examine the clinical effectiveness of nebulizer 
      inhalations of budesonide suspension during severe attacks of bronchial asthma 
      (BA) and the possibility of its use versus systemic glucocorticosteroids (GCSs). 
      Sixty-eight patients admitted for a severe attack of BA were examined. The forced 
      expiratory volume per sec (FEV1) was less than 40% and the peak forced expiration 
      rate (PFER) was less than 150 l/min. First-line therapy included inhaled 
      salbutamol (5-10 mg within 1.5-2 hours), oxygen, and intravenous prednisolone 
      (120 mg). Thirty-two patients showed a good response to first-line therapy (a 
      more than 50% increase in FEV1) as compared with the normal values) (Group 1) and 
      36 patients with concurrent obstructive lung disease (COLD) had an inadequate 
      response (FEV1 was less than 40% of the normal values) was found in 32 patients 
      (Group 2). Then the patients were randomized: 16 patients from Group 1 took 
      budesonide, 4 mg/day, the other 16 received intravenous prednisolone, 120 mg/day. 
      In Group 2, the efficacy of the drug added to therapy with oral prednisolone, 30 
      mg/day, was evaluated: 18 patients were given budesonide, 4 mg/day, and 18 
      received placebo. In patients with a good response to primary therapy, positive 
      clinical and functional changes were found on day 6 of treatment. Group 2 
      patients receiving budesonide showed a significantly (p < 0.05) more marked 
      positive changes in BA symptoms, FEV1, and PFER, which allowed a course of 
      therapy with systemic GCSs to be reduced. Nebulized budesonide may be used 
      instead of systemic GCSs to treat exacerbated BA if there is a good clinical and 
      functional response to first-line broncholytic therapy, which is indicative of 
      successful abatement of bronchospasm. If there is a poor response to first-line 
      therapy in patients with more severe BA concurrent COLD, the early use of 
      budesonide suspension in addition to systemic GCSs may enhance the efficiency of 
      therapy for BA attacks and reduce the volume of systemic steroidal therapy.
FAU - Sereda, V P
AU  - Sereda VP
FAU - Svistov, A S
AU  - Svistov AS
LA  - rus
PT  - Clinical Trial
PT  - English Abstract
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Effektivnost' nebulizirovannogo budesonida pri tiazhelom obostrenii bronkhial'noi 
      astmy.
PL  - Russia (Federation)
TA  - Klin Med (Mosk)
JT  - Klinicheskaia meditsina
JID - 2985204R
RN  - 0 (Bronchodilator Agents)
RN  - 51333-22-3 (Budesonide)
SB  - IM
MH  - Administration, Inhalation
MH  - Adult
MH  - Asthma/diagnosis/*drug therapy
MH  - Bronchodilator Agents/administration & dosage/*therapeutic use
MH  - Budesonide/administration & dosage/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nebulizers and Vaporizers
MH  - Severity of Illness Index
EDAT- 2004/09/04 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/04 05:00
PHST- 2004/09/04 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/04 05:00 [entrez]
PST - ppublish
SO  - Klin Med (Mosk). 2004;82(6):61-6.